국가: 남아프리카
언어: 영어
출처: South African Health Products Regulatory Authority (SAHPRA)
Lennon
BEVISPAS TABLETS SCHEDULING STATUS: S2 PROPRIETARY NAME (and dosage form): BEVISPAS TABLETS COMPOSITION: Each tablet contains: 135 mg mebeverine hydrochloride. PHARMACOLOGICAL CLASSIFICATION: A 11.2: Gastro-intestinal antispasmodics and cholinolytics. PHARMACOLOGICAL ACTION: Bevispas is a musculotropic spasmolytic agent with a selective action especially on smooth muscle spasms of the gastro- intestinal tract. No significant inhibition of normal peristalsis has been observed. INDICATIONS: Primary irritable colon characterised by persistent diarrhoea, alternating constipation and diarrhoea, abdominal pain and postprandial distension. Secondary irritable colon due to organic lesions such as diverticulitis, regional enteritis, specific and non-specific inflammatory conditions of the gastro-intestinal tract. CONTRA-INDICATIONS: Hypersensitivity to any ingredient in the product. Patients with porphyria. DOSAGE AND DIRECTIONS FOR USE: 135 mg mebeverine hydrochloride (one tablet) three times daily, preferably before meals. After a period of a few weeks the dosage may be gradually reduced once the desired effect has been obtained. Mebeverine hydrochloride is not contra- indicated in patients with glaucoma or prostatic hypertrophy, as atropine-like effects are absent. SIDE-EFFECTS AND SPECIAL PRECAUTIONS: Depression, headache, diarrhoea, constipation and dizziness have been reported after administration of Bevispas. KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT: See Side Effects and Special Precautions. Treatment is symptomatic and supportive. IDENTIFICATION: A white biconvex film coated tablet engraved with a mortar and pestle on one side. PRESENTATION: Securitainer packs of 100 tablets. Securitainer packs of 20 tablets. Securitainer packs of 500 tablets. STORAGE INSTRUCTIONS: Store below 30°C in tight 전체 문서 읽기